

Mitochondrial translation in trypanosomatids: a novel target for chemotherapy?

Moritz Niemann, André Schneider and Marina Cristodero*

Department of Chemistry and Biochemistry, University of Bern, Freiestr. 3, 3012 Bern, Switzerland

Trypanosomatids cause widespread disease in humans and animals. Treatment of many of these diseases is hampered by the lack of efficient and safe drugs. New strategies for drug development are therefore urgently needed. It has long been known that the single mitochondrion of trypanosomatids exhibits many unique features. Recently, the mitochondrial translation machinery of trypanosomatids has been the focus of several studies, which revealed interesting variations to the mammalian system. It is the aim of this article to review these unique features and to discuss them in the larger biological context. It is our opinion that some of these features represent promising novel targets for chemotherapeutic intervention that should be studied in more detail.

Mitochondrial translation

Mitochondria are double membrane-bounded organelles whose main function is oxidative phosphorylation. They have their own genome, which encodes a small number of proteins (e.g. 13 in humans). Most of the more than 1000 mitochondrial proteins are encoded in the nucleus, synthesized in the cytosol and finally imported into the organelle. However, the few mitochondrially encoded proteins are essential for oxidative phosphorylation indicating the need for mitochondrial protein synthesis. In line with the evolutionary origin of the mitochondrion, its translation system is of the bacterial type. It requires a formylated initiator tRNA^{Met}, bacterial-type translation factors and ribosomes whose rRNAs and structure resemble bacterial ones. The mammalian mitochondrial genome encodes 22 tRNA genes of bacterial evolutionary origin, a set predicted to be sufficient for translation of all codons. All of these tRNAs are aminoacylated by imported aminoacyl-tRNA synthetases which are by and large of the bacterial type. Mitochondria from many organisms use a variant genetic code; the most frequent variation is the reassignment of the stop codon UGA to tryptophan (reviewed in [1]).

Mitochondrial translation in trypanosomatids

The insect stage or procyclic form of *Trypanosoma brucei* produces energy mainly by oxidative phosphorylation

(reviewed in [2]). The bloodstream stage of *T. brucei*, however, lacks a functional respiratory chain and relies on glycolysis for energy production [2]. The mitochondrial genome of trypanosomatids encodes several proteins that are conventional for a mitochondrial genome (Box 1), as well as two rRNAs but no tRNAs. The lack of tRNAs is compensated for by import of a small fraction (1–10%) of cytosolic tRNAs [3]. Only two tRNAs are cytosol-specific, namely the initiator tRNA^{Met} and tRNA^{Sec} [3,4] (Figure 1). Unlike in mammals, all mitochondrial tRNAs of trypanosomatids are derived from nuclear-encoded tRNAs involved in cytosolic translation. Consequently, mitochondria of trypanosomatids have to function exclusively with eukaryotic-type tRNAs [5,6]. However, as in all eukaryotes, the mitochondrial translation system of trypanosomatids is of the bacterial type. Although many tRNAs might in principle be functionally interchangeable between the cytosol and mitochondria, this is not the case for the initiator tRNA^{Met} and for tRNAs that read codons that differ from the standard genetic code. Thus, at least in some cases adaptations of the mitochondrial translation system are required to functionally integrate imported eukaryotic-type tRNAs. These adaptations mainly concern factors that directly interact with tRNAs, such as aminoacyl-tRNA synthetases (aaRSs), translation initiation and elongation factors, but can ultimately also affect the ribosome (Figure 2).

Mitochondrial translation initiation

In mitochondria of *T. brucei*, a nuclear-encoded elongator tRNA^{Met} is used for both elongation and initiation [7]. After import, a fraction of the tRNA^{Met} becomes formylated by an unusual methionyl-tRNA^{Met} formyltransferase (MTF), which selectively recognizes elongator-type tRNA^{Met} [7]. The trypanosomal MTF is still homologous to other MTFs even though at 71.3 kDa it is approximately twice the size of any of the other known MTFs [7]. Finally, the formylated elongator tRNA^{Met} needs to bind to mitochondrial translation initiation factor 2 (mtIF2) before it can interact with the ribosome.

Ablation of mtIF2 leads to growth arrest in the procyclic form of *T. brucei*, whereas MTF, similar to what has been observed in yeast, seems dispensable [8]. However, these results were obtained in knockdown cell lines, thus it cannot be ruled out that the remaining amount of MTF suffices to sustain mitochondrial translation. Interestingly, cells with reduced levels of mtIF2 were affected by

Corresponding authors: Niemann, M. (niemann@dcb.unibe.ch); Cristodero, M. (marina.cristodero@izb.unibe.ch)

* Present address: Institute of Cell Biology, University of Bern, Baltzerstr. 4, Bern, Switzerland.

Box 1. Mitochondrially encoded proteins in trypanosomatids

The mitochondrial genome of *T. brucei* and most other trypanosomatids encodes three subunits of the cytochrome oxidase (Cox), cytochrome *b* (Cytb), several subunits of the NADH dehydrogenase, subunit 6 of the mitochondrial ATPase, a ribosomal protein and several as yet unidentified proteins [52]. Despite extensive efforts, mitochondrial translation has been notoriously difficult to study in trypanosomatids; one reason might be that most mitochondrially encoded proteins are highly hydrophobic which makes them difficult to resolve by gel electrophoresis and refractory to sequencing. Another reason is that mitochondria of trypanosomatids as of most eukaryotes cannot be genetically manipulated. However, using sophisticated two-dimensional gel electrophoresis in combination with *in organello* labeling and direct sequence analysis, it was possible to directly show that the open reading frames encoding Cox1, Cox2 and Cytb are indeed translated [46,47,53]. The processing steps required to produce the mature mRNAs encoding Cox2 and Cytb, unlike those for the Cox1 mRNA, include moderate U insertion/deletion-type RNA editing [54]. Interestingly, in contrast to the mitochondria of mammals, mitochondrial translation in *T. brucei* was resistant to chloramphenicol and many other translational inhibitors expected to block bacterial-type translation [47]. In the case of chloramphenicol the most probable explanation for this observation is the fact that the peptidyl transferase region in the mitochondrial rRNA, implicated in chloramphenicol binding, is partially missing [31].

reduced MTF activity, as cell growth was inhibited more severely in a combined knockdown cell line [8]. In *Leishmania major*, null mutants for the enzyme involved in the synthesis of 10-formyl tetrahydrofolate, a key intermediate for both purine synthesis and tRNA^{Met} formylation [9], are not viable [10]. Because trypanosomatids are known to be purine auxotrophs, this provides circumstantial evidence that in *Leishmania* spp. the formylation of the imported tRNA^{Met} might be essential.

In some cases, the formylmethionine needs to be removed for the newly synthesized proteins to be functional. This removal requires the sequential action of peptide deformylases (PDFs) and aminopeptidases [11]. Unlike human mitochondria, *T. brucei* has two distinct mitochon-




Figure 1. Genetic origin and localization of tRNAs in trypanosomatids. The mitochondrial genome of trypanosomatids does not encode any tRNAs, thus all tRNAs are encoded in the nucleus. Except for the cytosol-specific tRNA^{Met-i} and tRNA^{Sec} all cytosolic tRNAs are imported into the mitochondrion to variable extents (1–10%). As a consequence, all mitochondrial tRNAs of trypanosomatids are of the eukaryotic type and must function in the bacterial-type translation system of the mitochondrion.

drial PDFs, which are highly divergent from other eukaryotic PDFs. One of the enzymes was shown to be essential for the procyclic form [12]. Bacterial PDFs have been proven to be excellent drug targets indicating that the same might be the case for trypanosomatids [13].

Genetic code differences

In the mitochondria of trypanosomatids, as in most eukaryotes, the stop codon UGA has been reassigned to tryptophan. It is not obvious how the trypanosomal tRNA^{Trp} which in the cytosol exclusively recognizes the CCA codon can decode both the CCA and the UGA codons when present in mitochondria. Trypanosomatids solve this problem by a mitochondria-specific RNA editing event that converts the CCA anticodon of the imported tRNA^{Trp} to UCA, which allows decoding of both UGG and UGA triplets [14–16]. Thus, the use of the imported tRNA^{Trp} in mitochondrial translation requires an enzyme that catalyzes the C to U editing reaction. This trypanosomatid-specific enzyme could possibly make an excellent drug target; unfortunately, it has not been identified yet.

The imported tRNA^{Trp} is not only edited at the wobble nucleotide (C34 to U34), but the adjacent nucleotide U33 also becomes thiomodified [15]. Recently, it was shown that a reduction in the level of the thiomodification results in an increase of editing of the tRNA^{Trp} [17,18]. However, RNAi-mediated ablation of the mRNA encoding for one of the enzymes responsible for the thiomodification and the corresponding increase in tRNA^{Trp} editing did not affect growth of procyclic *T. brucei* [18,19]. Whether the thiomodification serves to regulate the extent of tRNA editing *in vivo* is therefore unclear at present.

Mitochondrial tryptophanyl-tRNA synthetase

In all eukaryotic organisms the mitochondrial aaRSs are encoded in the nucleus and imported into mitochondria [20]. Considering that all mitochondrial tRNAs of trypanosomatids are imported from the cytosol, the same aaRSs could in principle be used in both compartments. This is typically the case; for most aaRSs only one gene is found, and for some aaRSs dual localization has been confirmed [21]. The finding that two genes coding for cytosolic and mitochondrial versions of tryptophanyl-, aspartyl- and lysyl-tRNA synthetases (TrpRS, AspRS and LysRS) exist has therefore been puzzling.

In the case of the TrpRS, it was found that editing of the anticodon or thiolation of U33 of the imported tRNA^{Trp} changes an identity determinant (the ability of the TrpRS to identify the cognate tRNA, tRNA^{Trp}) for cytosolic TrpRS. *T. brucei* therefore needs two distinct TrpRSs: a cytosolic one (TbTrpRS1) that charges the tRNA^{Trp} with the anticodon CCA and a mitochondrial one (TbTrpRS2) that can aminoacylate the tRNA^{Trp} after it has been edited and/or thiolated [16].

Unlike the human mitochondrial enzyme, TbTrpRS2 is of eukaryotic origin. However, it is markedly divergent from its cytosolic counterpart TbTrpRS1, as well as from the cytosolic TrpRS of humans. Interestingly, it was recently shown that TbTrpRS2 is essential for proliferation of the bloodstream stage of *T. brucei* *in vitro* and for establishment of an infection in mice, making it another




Figure 2. Unique features of mitochondrial translation in *T. brucei*. The pathways and processes that show trypanosome-specific features are indicated in green with upper case letters. Enzymes and processes that participate in the different pathways that are conserved within most or all eukaryotes are depicted in black. Enzymes and structures that: (i) are specific for trypanosomes or that have unique features and (ii) that are expected to be essential and therefore are potential drug targets, are shown in red. The enzyme responsible for C to U editing of the imported tRNA^{Trp} is unknown. The imported tRNA^{Trp} is thiolated at U33, the nt 5' of the anticodon. The thiolation reaction is catalyzed by enzymes that (at least in part) are also required for the biogenesis of mitochondrial and cytosolic iron sulfur clusters [18,19]. It is unknown whether thiolation is essential, but it has been shown to prevent tRNA^{Trp} editing. tRNAs are most probably imported in their aminoacylated state but can be recharged inside mitochondria [37]. Abbreviations: MetRS, methionyl-tRNA synthetase; TrpRS2, eukaryotic-type mitochondrial tryptophanyl-tRNA synthetase; AspRS2, eukaryotic-type mitochondrial aspartyl-tRNA synthetase; LysRS2, mitochondrial lysyl-tRNA synthetase; mIF2, mitochondrial initiation factor 2; MTF, methionyl-tRNA formyltransferase; PDF1 and 2, peptide deformylase 1 and 2.

potential target for drug development [22]. It should be emphasized in this context that aaRSs have been successfully used as drug targets in bacteria and that cytosolic aaRSs have previously been proposed as drug targets in several parasitic protozoa (for a review see [23] and references therein; also consult Box 2).

Mitochondrial aspartyl- and lysyl-tRNA synthetases

The two other trypanosomal aaRSs encoded by two different genes, AspRS2 and LysRS2, have also been studied but are less well understood. For the two AspRSs the situation is analogous to the TrpRSs. Whereas both enzymes can charge the cytosolic tRNA^{Asp}, the mitochondrial tRNA^{Asp} can only be charged by the mitochondrial enzyme [24]. This different specificity is also probably due to an as yet uncharacterized compartment-specific modification(s) of the tRNA^{Asp}.

The situation is different for the LysRSs. The mitochondrial LysRS contains an N terminal extension that functions as a targeting signal and a C terminal one that blocks

Box 2. Aminoacyl-tRNA synthetases as drug targets

aaRSs catalyze the attachment of amino acids to their cognate tRNAs. Most organisms have at least 20 different aaRSs, one for each amino acid. aaRSs are universal and essential for cell viability, yet some of them differ markedly in structure from one organism to the other [23,55,56] and for this reason have long been proposed as targets for new antibiotics to treat bacterial infections. Many natural products have been described with the ability to inhibit different bacterial aaRSs. However, only one aaRS inhibitor, mupirocin, has been developed into a commercially available drug. Mupirocin was originally isolated from *Pseudomonas fluorescens* [57]. It inhibits isoleucyl-tRNA synthetases (IleRS) from Gram-positive bacterial pathogens including *Staphylococcus aureus*, *Streptococcus pyogenes* and *Staphylococcus epidermidis* [55]. More recently, aaRSs have also been suggested as drug targets in eukaryotic pathogens. Substances have been found that inhibit the activity of recombinant cytosolic LysRS of trypanosomes [58,59], and more recently inhibitors of the cytosolic MetRS of *T. brucei* were characterized that suppress the onset of trypanosomiasis in the mouse model [60]. aaRSs are attractive drug targets owing to the above-mentioned structural divergence [23,55,56] but also for several practical reasons that need to be taken into account for rational drug design: (i) many have been recombinantly expressed in a soluble and active state; (ii) their activity can be measured by methods amenable to high-throughput screening; (iii) the mechanism of catalysis of aaRSs has been extensively studied and is well understood; and (iv) the structures of many aaRSs are solved at high resolution, providing a platform on which more divergent aaRSs can be modeled. With this information in hand, the rational design of aaRSs inhibitors is within reach.

its function [25]. After import the N terminus of the mitochondrial LysRS is cleaved, and this in turn triggers processing of the C terminal extension resulting in an active protein. The substrate specificities of the cytosolic and mitochondrial LysRSs and why the activity of the mitochondrial enzyme has to be blocked when in transit to the mitochondria are currently unknown.

Mitochondrial ribosomes of trypanosomatids

Mitochondrial ribosomes in trypanosomatids are unique. Their small subunit (SSU) and the large subunit (LSU) rRNAs are extremely short, consisting of only 610 nt and 1150 nt (9 and 12S of *T. brucei*, respectively) [26–28]. Whereas the core regions of the peptidyl transferase center are conserved, other domains of the rRNAs are completely absent [29–31]. The mitochondrial ribosome of *T. brucei* consists of 133 proteins (77 in the LSU and 56 in the SSU) [32], which include orthologs of all mitochondrial ribosomal proteins that were previously identified in *Leishmania tarentolae* [30]. Mitochondrial ribosomes are known to contain more proteins than their bacterial counterparts. However, 133 is an extraordinarily high number compared to, for example, the 77 proteins present in the mammalian mitochondrial ribosome [33], indicating that some of the proteins might not be components of the stable ribosome but part of a super-complex that also performs other functions [32]. Only approximately 30% of the ribosome-associated proteins in *T. brucei* have orthologs in either bacteria or in other eukaryotes. The remaining 70% are unique to the trypanosomatids [32]. It has been suggested that the large number of ribosomal proteins in mitochondria of trypanosomatids might be needed to compensate for the markedly short rRNAs [32]. This view is supported by the recently solved Cryo-EM structure of the *L. tarentolae*

mitochondrial ribosome, which shows that despite the small rRNAs, the overall size and morphology of the particle is very similar to the bacterial ribosome [31].

In summary, even though presently no drug is known that specifically inhibits mitochondrial ribosomes of trypanosomatids, their unique composition makes them an excellent potential drug target.

Mitochondrial translation as drug target

Perhaps the unique features of mitochondrial translation in *T. brucei* and other trypanosomatids discussed above could offer as yet unexploited drug targets (Figure 2); interestingly, many of these features are directly or indirectly linked to the fact that trypanosomatid mitochondria need to import the entire set of tRNAs from the cytosol (reviewed in [6]).

Although the tRNA import machinery in *T. brucei* is very poorly characterized, a series of publications on the tRNA import system of *Leishmania tropica* are deemed highly controversial as has been discussed before [34]. Owing to concerns about the validity of these results [35,36], it is premature to discuss the value of the mitochondrial tRNA import system as a drug target. However, some of the adaptations of the mitochondrial translation system that allow it to use imported, eukaryotic-type tRNAs have been characterized in sufficient detail to evaluate them as serious drug targets (Figure 2 and Box 2, [37]). One of the key questions in this context is whether or not mitochondrial translation is in fact essential in the disease-causing forms of trypanosomatids.

In *T. brucei* this question has recently been the focus of much interest. Bloodstream forms of *T. brucei* do not perform oxidative phosphorylation but produce their energy exclusively by glycolysis (reviewed in [2]). Most of the mitochondrially encoded genes in trypanosomes code for components required for oxidative phosphorylation (Box 1) and therefore might not be expressed in the bloodstream form. Moreover, *T. brucei* strains exist that are lacking mitochondrial DNA; these so-called dyskinetoplasmic strains are locked in the bloodstream stage (see [38] and references therein). These observations suggested that mitochondrial translation is dispensable in the bloodstream form. In addition, a recent publication reports the failure to detect *de novo* synthesized proteins in bloodstream form mitochondria [39]. Nevertheless, several studies also showed that kinetoplast DNA replication [40], mitochondrial transcription [41] and RNA editing [42] are essential throughout the life cycle of *T. brucei*. Moreover, these results were confirmed by more direct investigations of the mitochondrial translation system. It is now known that survival of the bloodstream form of *T. brucei* depends on the mitochondrial ATP synthase, one subunit of which is mitochondrially encoded and translated. In this life stage, the ATP synthase functions in reverse, consuming mitochondrial ATP to pump protons to the intermembrane space. In this way it generates the membrane potential that is needed to maintain transport of metabolites and proteins across the mitochondrial inner membrane [43,44]. But how can dyskinetoplasmic strains survive? To explain this conundrum it has been hypothesized that dyskinetoplasmic forms of *T. brucei* contain com-

pensatory mutations in one nuclear-encoded subunit of the mitochondrial ATP synthase that allow it to hydrolyze ATP even in the absence of the mitochondrially encoded subunit [38,44,45].

Data on mitochondrial translation in *Leishmania* spp. or *Trypanosoma cruzi* are scarce. In *L. tarentolae*, it has been shown that mitochondrial translation takes place in the promastigote stage that occurs in the sand fly [46,47]. The respiratory chain is present in both the amastigote and the promastigote life stages of *Leishmania* spp. [2]. Several studies suggest that the respiratory chain could be a target for chemotherapy [48,49]. The mitochondrial metabolism of *Leishmania* spp. therefore bears a resemblance to pro-cyclic *T. brucei* [2]. The same appears to be the case for the trypomastigote and epimastigote forms of *T. cruzi* [2,50,51].

Concluding remarks

Since the advent of antibiotics, protein synthesis has been a classic target for antibacterial compounds. Analogously, many of the unique features of mitochondrial protein synthesis discussed above will provide novel drug targets against all major trypanosomatid pathogens, if further investigated in the future. It is now clear that mitochondrial translation is essential for bloodstream forms of *T. brucei*. However, experiments regarding the inhibition or ablation of specific translation factors and the resulting consequences on parasite survival in the bloodstream stage are missing. The same is the case for *T. cruzi* and *Leishmania* spp. This is unfortunate as a pilot study has shown that the mitochondrial translation elongation factor Tu and TrpRS2 are indeed essential for survival of bloodstream form of *T. brucei*, suggesting that further studies in this direction might be very rewarding [22]. We hope this article stimulates discussion regarding the mitochondrial translation system in pathogenic eukaryotes as a potential drug target, and the sparks of this discussion ignite further research efforts beyond the trypanosomatid field.

References

- 1 Knight, R.D. *et al.* (2001) Rewiring the keyboard: evolvability of the genetic code. *Nat. Rev. Genet.* 2, 49–58
- 2 Tielens, A.G. and van Hellemond, J.J. (2009) Surprising variety in energy metabolism within Trypanosomatidae. *Trends Parasitol.* 25, 482–490
- 3 Tan, T.H. *et al.* (2002) tRNAs in *Trypanosoma brucei*: genomic organization, expression, and mitochondrial import. *Mol. Cell Biol.* 22, 3707–3717
- 4 Bouzaidi-Tiali, N. (2007) Elongation factor 1a mediates the specificity of mitochondrial tRNA import in *T. brucei*. *EMBO J.* 26, 4302–4312
- 5 Alfonzo, J.D. and Söll, D. (2009) Mitochondrial tRNA import – the challenge to understand has just begun. *Biol. Chem.* 390, 717–722
- 6 Lithgow, T. and Schneider, A. (2010) Evolution of macromolecular import pathways in mitochondria, hydrogenosomes and mitosomes. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 365, 799–817
- 7 Tan, T.H. *et al.* (2002) Eukaryotic-type elongator tRNA^{Met} of *Trypanosoma brucei* becomes formylated after import into mitochondria. *Proc. Natl. Acad. Sci. U.S.A.* 99, 1152–1157
- 8 Charriere, F. *et al.* (2005) Mitochondrial initiation factor 2 of *Trypanosoma brucei* binds imported formylated elongator-type tRNA(Met). *J. Biol. Chem.* 280, 15659–15665
- 9 Vickers, T.J. *et al.* (2009) The enzymes of the 10-formyl-tetrahydrofolate synthetic pathway are found exclusively in the cytosol of the trypanosomatid parasite *Leishmania major*. *Mol. Biochem. Parasitol.* 166, 142–152

- 10 Murta, S.M. *et al.* (2009) Methylene tetrahydrofolate dehydrogenase/cyclohydrolase and the synthesis of 10-CHO-THF are essential in *Leishmania major*. *Mol. Microbiol.* 71, 1386–1401
- 11 Giglione, C. *et al.* (2004) Protein N-terminal methionine excision. *Cell. Mol. Life Sci.* 61, 1455–1474
- 12 Bouzaidi-Tiali, N. *et al.* (2007) Type 3 peptide deformylases are required for oxidative phosphorylation in *Trypanosoma brucei*. *Mol. Microbiol.* 65, 1218–1228
- 13 Giglione, C. and Meinel, T. (2001) Peptide deformylase as an emerging target for antiparasitic agents. *Expert Opin. Ther. Targets* 5, 41–57
- 14 Alfonso, J.D. *et al.* (1999) C to U editing of the anticodon of imported mitochondrial tRNA(Trp) allows decoding of the UGA stop codon in *Leishmania tarentolae*. *EMBO J.* 18, 7056–7062
- 15 Crain, P.F. *et al.* (2002) Modification of the universally unmodified uridine-33 in a mitochondria-imported edited tRNA and the role of the anticodon arm structure on editing efficiency. *RNA* 8, 752–761
- 16 Charriere, F. *et al.* (2006) Dual targeting of a single tRNA(Trp) requires two different tryptophanyl-tRNA synthetases in *Trypanosoma brucei*. *Proc. Natl. Acad. Sci. U.S.A.* 103, 6847–6852
- 17 Wohlgamuth-Benedum, J.M. *et al.* (2009) Thiolation controls cytoplasmic tRNA stability and acts as a negative determinant for tRNA editing in mitochondria. *J. Biol. Chem.* 284, 23947–23953
- 18 Bruske, E.I. *et al.* (2009) Thiolated tRNAs of *Trypanosoma brucei* are imported into mitochondria and dethiolated after import. *J. Biol. Chem.* 284, 36491–36499
- 19 Paris, Z. *et al.* (2010) The Fe/S cluster assembly protein Isd11 is essential for tRNA thiolation in *Trypanosoma brucei*. *J. Biol. Chem.* 285, 22394–22402
- 20 Duchene, A.M. *et al.* (2009) Import of tRNAs and aminoacyl-tRNA synthetases into mitochondria. *Curr. Genet.* 55, 1–18
- 21 Rinehart, J. *et al.* (2004) Non-canonical eukaryotic glutamyl- and glutamyl-tRNA synthetases form mitochondrial aminoacyl-tRNA in *Trypanosoma brucei*. *J. Biol. Chem.* 279, 1161–1166
- 22 Cristodero, M. *et al.* (2010) Mitochondrial translation is essential in bloodstream forms of *Trypanosoma brucei*. *Mol. Microbiol.* 78, 757–769
- 23 Ochsner, U.A. *et al.* (2007) Aminoacyl-tRNA synthetases: essential and still promising targets for new anti-infective agents. *Expert Opin. Investig. Drugs* 16, 573–593
- 24 Charriere, F. *et al.* (2009) Dual targeting of a tRNA^{Asp} requires two different aspartyl-tRNA synthetases in *Trypanosoma brucei*. *J. Biol. Chem.* 284, 16210–16217
- 25 Espanol, Y. *et al.* (2009) A mechanism for functional segregation of mitochondrial and cytosolic genetic codes. *Proc. Natl. Acad. Sci. U.S.A.* 106, 19420–19425
- 26 Eperon, I.C. *et al.* (1983) The major transcripts of the kinetoplast DNA of *Trypanosoma brucei* are very small ribosomal RNAs. *Nucleic Acids Res.* 11, 105–125
- 27 de la Cruz, V.F. *et al.* (1985) A minimal ribosomal RNA: sequence and secondary structure of the 9S kinetoplast ribosomal RNA from *Leishmania tarentolae*. *Proc. Natl. Acad. Sci. U.S.A.* 82, 1401–1405
- 28 de la Cruz, V.F. *et al.* (1985) Primary sequence and partial secondary structure of the 12S kinetoplast (mitochondrial) ribosomal RNA from *Leishmania tarentolae*: conservation of peptidyl-transferase structural elements. *Nucleic Acids Res.* 13, 2337–2356
- 29 Maslov, D.A. *et al.* (2006) Isolation and characterization of mitochondrial ribosomes and ribosomal subunits from *Leishmania tarentolae*. *Mol. Biochem. Parasitol.* 148, 69–78
- 30 Maslov, D.A. *et al.* (2007) Proteomics and electron microscopic characterization of the unusual mitochondrial ribosome-related 45S complex in *Leishmania tarentolae*. *Mol. Biochem. Parasitol.* 152, 203–212
- 31 Sharma, M.R. *et al.* (2009) Structure of a mitochondrial ribosome with minimal RNA. *Proc. Natl. Acad. Sci. U.S.A.* 106, 9637–9642
- 32 Ziková, A. *et al.* (2008) *Trypanosoma brucei* mitochondrial ribosomes: affinity purification and component identification by mass spectrometry. *Mol. Cell. Proteomics* 7, 1286–1296
- 33 Sharma, M.R. *et al.* (2003) Structure of the mammalian mitochondrial ribosome reveals an expanded functional role for its component proteins. *Cell* 115, 97–108
- 34 Salinas, T. *et al.* (2008) Recent advances in tRNA mitochondrial import. *Trends Biochem. Sci.* 33, 320–329
- 35 Goswami, S. *et al.* (2006) A bifunctional tRNA import receptor from *Leishmania* mitochondria. *Proc. Natl. Acad. Sci. U.S.A.* 103, 8354–8359
- 36 Schekman, R. (2010) Editorial expression of concern and correction. *Proc. Natl. Acad. Sci. U.S.A.* 107, 9476
- 37 Schneider, A. (2011) Mitochondrial tRNA import and its consequences for mitochondrial translation. *Annu. Rev. Biochem.* DOI:10.1146/annurev-biochem-060109-092838
- 38 Schnauffer, A. *et al.* (2002) Natural and induced dyskinetoplastic trypanosomatids: how to live without mitochondrial DNA. *Int. J. Parasitol.* 32, 1071–1084
- 39 Richterova, L. *et al.* (2011) DEAD-box RNA helicase is dispensable for mitochondrial translation in *Trypanosoma brucei*. *Exp. Parasitol.* 127, 300–303
- 40 Timms, M.W. *et al.* (2002) Mitochondrial development during life cycle differentiation of African trypanosomes: evidence for a kinetoplast-dependent differentiation control point. *Mol. Biol. Cell* 13, 3747–3759
- 41 Paris, Z. *et al.* (2011) Futile import of tRNAs and proteins into the mitochondrion of *Trypanosoma brucei evansi*. *Mol. Biochem. Parasitol.* 176, 116–120
- 42 Schnauffer, A. *et al.* (2001) An RNA ligase essential for RNA editing and survival of the bloodstream form of *Trypanosoma brucei*. *Science* 291, 2159–2162
- 43 Vercesi, A.E. *et al.* (1992) Energization-dependent Ca²⁺ accumulation in *Trypanosoma brucei* bloodstream and procyclic trypomastigotes mitochondria. *Mol. Biochem. Parasitol.* 56, 251–257
- 44 Schnauffer, A. *et al.* (2005) The F1-ATP synthase complex in bloodstream stage trypanosomes has an unusual and essential function. *EMBO J.* 24, 4029–4040
- 45 Lai, D.H. *et al.* (2008) Adaptations of *Trypanosoma brucei* to gradual loss of kinetoplast DNA: *Trypanosoma equiperdum* and *Trypanosoma evansi* are petite mutants of *T. brucei*. *Proc. Natl. Acad. Sci. U.S.A.* 105, 1999–2004
- 46 Horváth, A. *et al.* (2000) Detection of the mitochondrially encoded cytochrome c oxidase subunit I in the trypanosomatid protozoan *Leishmania tarentolae*. Evidence for translation of unedited mRNA in the kinetoplast. *J. Biol. Chem.* 275, 17160–17165
- 47 Horváth, A. *et al.* (2002) Unusual polypeptide synthesis in the kinetoplast-mitochondria from *Leishmania tarentolae*. Identification of individual *de novo* translation products. *J. Biol. Chem.* 277, 7222–7230
- 48 Bermudez, R. *et al.* (1997) Characterization of mitochondrial electron-transfer in *Leishmania mexicana*. *Mol. Biochem. Parasitol.* 90, 43–54
- 49 Zhai, L. *et al.* (1999) The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. *J. Antimicrob. Chemother.* 43, 793–803
- 50 Aldunate, J. *et al.* (1992) Effects of hydroquinones on intact *Trypanosoma cruzi* epimastigotes. *Comp. Biochem. Physiol. C* 103, 97–100
- 51 Denicola-Seoane, A. *et al.* (1992) Succinate-dependent metabolism in *Trypanosoma cruzi* epimastigotes. *Mol. Biochem. Parasitol.* 54, 43–50
- 52 Feagin, J.E. (2000) Mitochondrial genome diversity in parasites. *Int. J. Parasitol.* 30, 371–390
- 53 Horváth, A. *et al.* (2000) Translation of the edited mRNA for cytochrome b in trypanosome mitochondria. *Science* 287, 1639–1640
- 54 Stuart, K.D. *et al.* (2005) Complex management: RNA editing in trypanosomes. *Trends Biochem. Sci.* 30, 97–105
- 55 Schimmel, P. *et al.* (1998) Aminoacyl tRNA synthetases as targets for new anti-infectives. *FASEB J.* 12, 1599–1609
- 56 Kim, S. *et al.* (2003) Aminoacyl-tRNA synthetases and their inhibitors as a novel family of antibiotics. *Appl. Microbiol. Biotechnol.* 61, 278–288
- 57 Fuller, A.T. *et al.* (1971) Pseudomonic acid: an antibiotic produced by *Pseudomonas fluorescens*. *Nature* 234, 416–417
- 58 Farrera-Sinfreu, J. *et al.* (2008) Solid-phase combinatorial synthesis of a lysyl-tRNA synthetase (LysRS) inhibitory library. *J. Comb. Chem.* 10, 391–400
- 59 Ding, D. *et al.* (2011) Design, synthesis and structure-activity relationship of *Trypanosoma brucei* leucyl-tRNA synthetase inhibitors as antitrypanosomal agents. *J. Med. Chem.* 54, 1276–1287
- 60 Shibata, S. *et al.* (2011) Selective inhibitors of methionyl-tRNA synthetase have potent activity on *Trypanosoma brucei* infection in mice. *Antimicrob. Agents Chemother.* DOI:10.1128/AAC.01796-10.